Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Allogeneic bone marrow transplantation
- Development stage
- Unknown
- Lead developer
- Medical College of Wisconsin
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous
01
Overview
Allogeneic bone marrow transplantation (BMT) is a cell-based therapy involving the infusion of hematopoietic stem cells obtained from the bone marrow of an HLA-compatible donor into a recipient. This procedure is primarily utilized for the treatment of high-risk hematologic malignancies, including acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), chronic myeloid leukemia (CML), myelodysplastic syndromes (MDS), and myeloproliferative disorders. The therapeutic effect is twofold: first, the donor cells reconstitute the recipient's hematopoietic system following myeloablative or reduced-intensity conditioning; second, the donor-derived immune cells exert a graft-versus-leukemia (GVL) effect, identifying and eliminating residual malignant cells. The Medical College of Wisconsin served as the lead sponsor for the Phase III BMT CTN #0201 trial, which compared the efficacy and safety of bone marrow-derived cells against G-CSF-mobilized peripheral blood stem cells in the unrelated donor setting.
- Other names
- Allogeneic bone marrow transplantAllo-BMTUnrelated donor bone marrow transplantation
Beyond the preview
Go deeper on Allogeneic bone marrow transplantation.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Allogeneic bone marrow transplantation.